# JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations

> **NCT06940401** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Junjing BioSciences Co., Ltd.** · enrollment: 42 (estimated)

## Conditions studied

- NSCLC

## Interventions

- **DRUG:** JS111 capsules (AP-L1898)

## Key facts

- **NCT ID:** NCT06940401
- **Lead sponsor:** Suzhou Junjing BioSciences Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-30
- **Primary completion:** 2025-12-31
- **Final completion:** 2027-11-05
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06940401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06940401, "JS111 in Patients With Advanced NSCLC Harboring EGFR Mutations". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06940401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*